Formulaciones intranasales bajo la forma de explantes o spray

Colchicine Plus Fosfomycin In Coronavirus Infection Claudio Cerati* Polymicrocaps, Argentina 

Opinion 

1. Following Covid-19 outbreak, the scientific community focused on several alternatives for either preventing or therapeutically treating the illness. 

2. It is clear enough at this time that vaccines will not be available at least for the few months to came. An association between an antibiotic (Azithromycin) and an antimalarial drug (chloroquine) has already been tested. 

3. Safety and toxicity issues has raised some concern regarding Chloroquine doses needed to reach a therapeutic activity and some clinical trials must be aborted ( Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2 (CloroCOVID19) this study was registered with ClinicalTrials.gov, number NCT04323527). 

4. Some antibiotics can act as immunomodulators and particularly, Fosfomycin, has an immunomodulatory effect on human B-cell activation. Fosfomycin is considered an unique antibiotic which is chemically unrelated to any other known antibacterial agent. The effect of Fosfomycin on human T-cells function was yet studied and the inhibition of proliferation of human lymphocytes induced induced by polyclonal T-cell mitogens studied as a function of Fosfomycin dose. 

5. It was also described the supression by Fosfomycin of mixed lymphocyte reaction and interleukin-2 (IL-2) production by T cells along with the expression of IL-2 receptor (CD25) on the activated T-cell surfaces. Previous research demonstrated that Fosfomycin blocks T-cell division during the transition from G1 to S phase of the cell cycle.

 6. Actually it is also known that SARS Coronavirus replicates in mononuclear cells of peripheral blood (PBMCs) from SARS infected patients (Journal of Clinical Virology, Vol 28,Issue 3, December 2003, Pag 239-244).

 7. Fosfomycin exerts a direct effect on proliferation of PBMC when stimulated with Concanavalin A, in fact , at concentrations between 1,6 to 200 micrograms/ml , particularly, 50% inhibition of T-cell proliferation was observed at the dose range between 8 and 40 micrograms/ml. It was also found that this antiproliferative effect had no relationship with antibiotic activity since the inactive enantiomer had the same antiproliferative effect than the active optical enantiomer responsible for the antibacterial effect.

 8. Effect of oral colchicine on T cell subsets, monocytes and Concanavalin A‐induced suppressor cell function in asthmatic patient was studied by Dr D. N. Ilfeld of the Institute of Pulmonary Diseases and Clinical Pharmacology Unit,( Beilinson Medical Center, Petah Tikva; Department of Cell Biology, Weizmann Institute of Science, Rehovot; and Clinical Immunology Laboratory, Soroka Medical Center, Beer Sheva, Israel)

 *Corresponding author: Claudio Cerati, Director of Research and Development of New Products, Polymicrocaps, Argentina Submission: April 20, 2020 Published: April 29, 2020 Volume 3 - Issue 1

 How to cite this article: Claudio Cerati. Colchicine Plus Fosfomycin In Coronavirus Infection. Mod Appro Drug Des. 3(1). MADD.000551.2020. DOI: 10.31031/MADD.2020.03.000551 Copyright@ Claudio Cerati. 

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited.